Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy.
about
Ubiquitin signaling in immune responsesMesenchymal Stem Cell-Derived Extracellular Vesicles Promote Angiogenesis: Potencial Clinical ApplicationP53 mutations in colorectal cancer - molecular pathogenesis and pharmacological reactivationMdm2 as a chromatin modifierFunctional activation of mutant p53V172F by platinum analogs in cisplatin-resistant human tumor cells is dependent on serine-20 phosphorylationAn observational study on the expression levels of MDM2 and MDMX proteins, and associated effects on P53 in a series of human liposarcomasUSP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responsesTherapeutic efficacy of p53 restoration in Mdm2-overexpressing tumors.DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.MicroRNA binding site polymorphisms as biomarkers in cancer management and research.Tissue-specific and age-dependent effects of global Mdm2 lossIdentification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice.MicroRNA and mRNA cargo of extracellular vesicles from porcine adipose tissue-derived mesenchymal stem cells.Limiting the power of p53 through the ubiquitin proteasome pathway.Genomic aberrations of MDM2, MDM4, FGFR1 and FGFR3 are associated with poor outcome in patients with salivary gland cancer.Targeting survivin in cancer: novel drug development approaches.Hsp90 inhibitor BIIB021 enhances triptolide-induced apoptosis of human T-cell acute lymphoblastic leukemia cells in vitro mainly by disrupting p53-MDM2 balanceWild type p53 reactivation: from lab bench to clinic.MicroRNA-410 suppresses migration and invasion by targeting MDM2 in gastric cancer.Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.The cell cycle regulator CCDC6 is a key target of RNA-binding protein EWS.MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition.Bridged Analogues for p53-Dependent Cancer Therapy Obtained by S-AlkylationUXT, a novel MDMX-binding protein, promotes glycolysis by mitigating p53-mediated restriction of NF-κB activityTargeting RING domains of Mdm2-MdmX E3 complex activates apoptotic arm of the p53 pathway in leukemia/lymphoma cellsIdentification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53.The MDM2-p53 pathway revisitedRelationship Between Murine Double Minute 2 (MDM2) T309G Polymorphism and Endometrial Cancer Risk: A Meta-Analysis.Novel perspective: exercise training stimulus triggers the expression of the oncoprotein human double minute-2 in human skeletal muscle.miR-661 downregulates both Mdm2 and Mdm4 to activate p53.MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53.Essential Roles of E3 Ubiquitin Ligases in p53 Regulation.The Regulations of Deubiquitinase USP15 and Its Pathophysiological Mechanisms in Diseases.The Mdm network and its regulation of p53 activities: a rheostat of cancer risk.Ubiquitination in disease pathogenesis and treatment.Pharmacological reactivation of p53 as a strategy to treat cancer.Dysfunction of the MDM2/p53 axis is linked to premature aging.2-Indolinone a versatile scaffold for treatment of cancer: a patent review (2008-2014).Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.Regulation of Mdm2 protein stability and the p53 response by NEDD4-1 E3 ligase.
P2860
Q26751376-C11EB6BC-F210-4770-9A53-5C81661D4889Q26768162-A36CCFB3-47B2-4A06-B5C4-0C9815EF0A53Q27021759-015ECE95-2700-4E69-9606-D88E4C31F4E7Q28073903-A3A9F469-7B08-459F-AEB9-EE1510DCD957Q29248201-2855976B-8D7D-4BCB-8B22-FA76521E6C84Q33640890-5125F0F4-A036-40F2-8079-42E7C40CF6B7Q33655162-60B5847D-6A17-404D-9FCB-2EE4388AA305Q33758339-8CE4A991-5818-42FD-AB88-417A67FBB295Q33787360-8F97B601-2C75-4CD2-89C3-43F917DB5062Q34019040-4E83D47E-E5FB-4C2F-88D5-02F9A510CE1FQ34121104-C04E419B-3447-49E8-AD77-E9AE53068586Q34218811-34B4C72D-B141-415C-B7A5-B150CE172701Q34241814-8F29ABB6-10EA-4DA8-AF65-AF006AD5B3C7Q34342940-B723C99C-EE1A-452C-8C17-C4C8F1CAC61FQ34504939-8D2468CE-4939-42F0-8A06-034DD6ED9D9CQ34954296-2C98D162-3515-4106-964D-8ABB91DEEC9FQ35044980-BAB9E43E-16DF-43FB-9941-5007D2BF6DE2Q35146343-70B57847-2943-40C7-A943-AC538D0E1E5DQ35227870-BF7E86A6-EBBC-4215-AFF0-43F023AADBBEQ35550054-3CA650F5-DB62-4E5C-8C0F-AF731EABA0BFQ35573610-7E1E494F-5DA7-4F91-8564-C38C59C0ACC3Q35781547-2A262B00-4C1F-49D0-A35D-420DCAEAB3E5Q35950537-A90D6CA8-94B6-48C4-B905-695D26D216C6Q36232109-5557D969-0933-41EA-AE04-C1F8C76B9674Q36485161-EBFEA3D7-6C75-4990-B65F-DAC420EA24B0Q36917788-75E678FD-85E5-4F16-AA84-6DC7997997D9Q37039474-52B2467C-98E2-4636-AE69-41C3A974D5C5Q37261592-CC27BC72-0842-468D-B74F-0C0882714435Q37319406-6857DE4C-4F10-4DAD-87BE-485E9B28EB4CQ37475492-31DC3D87-31BC-40A9-A945-D459C19DF495Q37688946-2D382369-BF07-43E1-BA30-5FF60BDC253FQ37691041-939A66A2-D3D5-4B80-AFE1-5858314EACD4Q37728992-FF22008E-643E-4415-83B0-68C0D0CBE678Q38184520-45474C7E-5438-4B4D-A3C3-632F2A34C81CQ38265657-482B88F3-CC77-44C0-91AE-6F1F76CEA47DQ38286198-08F1B9DF-7693-4BC3-9ABA-04C12757358FQ38605937-91D39B84-AAF4-448D-93C9-09A9D53302DFQ38631566-516C48DD-1D16-46FF-B5BA-0AFED43195FBQ38797572-F22BCEA0-310F-44E2-A875-3F91F3886506Q39035366-72DB1B1F-43C1-4A19-8FD1-1441E7FA1AC7
P2860
Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy.
@en
type
label
Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy.
@en
prefLabel
Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy.
@en
P2860
P1476
Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy.
@en
P2093
Guillermina Lozano
P2860
P356
10.1158/1078-0432.CCR-12-0053
P407
P577
2012-12-21T00:00:00Z